Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384500 | 0.88 | MAPT (0.54) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL30627005 | 0.88 | MAPT (0.54) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL4801780 | 0.82 | MAPT (0.46) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL9431947 | 0.78 | F9 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31370833 | 0.78 | CSNK2A2 (0.44) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL9432296 | 0.78 | CSNK2A2 (0.41) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL15203667 | 0.77 | CSNK2A2 (0.49) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL9431731 | 0.77 | F9 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9431710 | 0.77 | HDAC1 (0.52) | KDM4EMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL9431176 | 0.77 | MAPT (0.49) | KDM4EMAPTHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024232599-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE INHIBITING BET PROTEIN AND COMPOSITION FOR TREATMENT OF CANCER, USING SAME | 주식회사 베노바이오 | 2024-11-14 | — | — | WO | disclosed |
| EP-1456196-B1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1456196-A1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6730670-B2 | FOR PROPHYLAXIS OF ILLNESSES BASED ON MODULATION OF ADENOSINE SYSTEM, SUCH AS ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, NEUROPROTECTION, SCHIZOPHRENIA, ANXIETY, PAIN, RESPIRATION DEFICITS, DEPRESSION, DRUG ADDICTION | HOFFMANN-LA ROCHE INC. | 2004-05-04 | — | — | US | disclosed |
| US-20030149030-A1 | 7-phenyl-benzo [b] thiophen amide derivatives | HOFFMANN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003053954-A1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053954-A1 | BENZOTHIOPHENES AS ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149030-A1 | 7-phenyl-benzo [b] thiophen amide derivatives | ADORA2A, ADORA2B, ADORA1 | KDM4E 3547/4885MAPT 4024/4885HDAC3 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.